Candidaemia associated with decreased in vitro fluconazole susceptibility: Is Candida speciation predictive of the susceptibility pattern?

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1460-1465

  Oxman, David A ^a,b   Chow, Jennifer K ^a   Frendl, Gyorgy ^b   Hadley, Susan ^a   Hershkovitz, Shay ^b   Ireland, Peter ^b   McDermott, Laura A ^a   Tsai, Katy ^a   Marty, Francisco M ^b   Kontoyiannis, Dimitrios P ^c   Golan, Yoav ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antibiotic resistance; Antifungals; Candidiasis; Fungal infections

Indexed keywords

FLUCONAZOLE; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ADULT; CANDIDA; CANDIDIASIS; CLASSIFICATION; DRUG EFFECTS; FUNGEMIA; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 77954203947     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq136     Document Type: Article

References (24)

1. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
2. Rocco TR, Reinert SE, Simms HH. Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch Surg 2000; 135: 160-5.
3. Gleason TG, May AK, Caparelli D et al. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997; 132: 1197-201.
4. Arendrup MC, Fuursted K, Gahrn-Hansen B et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Mirobiol Infect 2008; 14: 487-94.
5. Lopez J, Pernot C, Aho S et al. Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. J Hosp Infect 2001; 48: 122-8.
6. Muñoz P, Sánchez-Somolinos M, Alcalá L et al. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 2005; 55: 188-93.
7. Samonis G, Kofteridis DP, Saloustros E et al. Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data. Scand J Infect Dis 2008; 40: 414-9.
8. Cuenca-Estrella M, Rodriguez D, Almirante B et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55: 194-9.
9. Johnson E, Espinel-Ingroff A, Szekely A et al. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies. Int J Antimicrob Agents 2008; 32: 511-4.
10. Klevay MJ, Ernst EJ, Hollanbaugh JL et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2008; 60: 273-7.
11. Morrel M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
12. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
13. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
14. Clinical and Laboratory Standards Institute. Zone Diameter Interpretive Stardards, Corresponding Minimal Inhibitory Concentration (MIC) Interpretive Breakpoints, and Quality Control Limits for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Informational Supplement M44-S2. CLSI, Wayne, PA, USA, 2007.
15. Chow JK, Golan Y, Ruthazer R et al. Factors associated with candidemia caused by non albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008; 46: 1206-13.
16. Chow JK, Golan Y, Ruthazer R et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008; 36: 1993-8.
17. Playford EG, Marriott D, Nguyen Q et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med 2008; 36: 2034-9.
18. Shorr AF, Lazarus DR, Sherner JH et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infection? Potential implications of the increasing prevalence on non-albicans candidemia. Crit Care Med 2007; 35: 1077-83.
19. Husni R, Hachem R, Hanna H et al. Risk factors for vancomycin-resistant Enterococcus infection in colonized patients with cancer. Infect Control Hosp Epidemiol 2002; 23: 102-3.
20. Harris AD, McGregor JC, Johnson JA et al. Risk factors for colonization with extended-spectrum b-lactamase-producing bacteria and intensive care unit admission. Emerg Inf Dis 2007; 13: 1144-9.
21. Tornieporth NG, Roberts RB, John J et al. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996; 23: 767-72.
22. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: 1735-45.
23. Reller ME, Mallonee AB, Kwiatkowski NP et al. Use of peptide nucleic acid-fluorescence in situ hybridization for definitive, rapid identification of five common Candida species. J Clin Microbiol 2007; 45: 3802-3.
24. Alexander BD, Ashley ED, Reller LB et al. Cost savings with implementation of PNA FISH testing for identification of Candida albicans in blood cultures. Diagn Microbiol Infect Dis 2006; 54: 277-82.